Meeting
2021 ASCO Annual Meeting
A comprehensive literature review and meta-analysis on prognostic value of BRCAm, HRRm and HRD+ across tumor types.
Authors
Changxia Shao
Merck & Co., Inc., Kenilworth, NJ
Changxia Shao , Andrew Marley , Huilin Tang , Jun Wan , Chelsey Miller , Madeline Brown , Yiqing Song , Jiali Han , Gboyega Adeboyeje
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3125)
DOI
10.1200/JCO.2021.39.15_suppl.3125
Abstract #
3125
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Homologous recombination repair (HRR) alterations may be passenger events in patients with advanced prostate cancer (PC) with high tumor mutational burden (hTMB).
First Author: Vineel Bhatlapenumarthi
Poster
2022 ASCO Annual Meeting
Establishment of a novel BRCAness score that predicts response to PARP inhibitors.
First Author: Masanori Oshi
Poster
2022 ASCO Genitourinary Cancers Symposium
Interrelation of functional homologous recombination deficiency and hrr pathway alterations in prostate cancer.
First Author: Jason Zhu
Poster
2022 ASCO Genitourinary Cancers Symposium
Identification of homologous recombination and repair (HRR) deficiency using circulating tumor DNA (ctDNA) in advanced prostate cancer (aPC).
First Author: Leslie A. Bucheit